₹1925.9
+4.55% today
· 30d -0.52%
as of 2026-09-04
Price · Daily Candles
“Emcure Pharma's quarterly profit soars 23.58% YoY, even as FIIs trim stakes and FCF growth remains a challenge.”
Emcure Pharma reported Q4 FY26 net profit growth of 23.58% YoY to ₹244 crore, driven by a 16.7% YoY revenue increase to ₹2470 crore. The company maintains a strong performance score of 100 and growth score of 76 according to our business metrics, yet faces challenges with free cash flow, which shows a weak ML prediction rank for 1-year growth (0.11 for recent 2-year and 0.0 for rolling 4-year and stable 7-year models).
BULL CASE
+Net profit in Q4 FY26 grew by 23.58% YoY to ₹244 crore, alongside a 16.7% YoY revenue increase.
+Annual revenue for FY26 reached ₹9204 crore, with net profit hitting ₹941 crore, marking a 33.05% YoY increase.
+The 3-year revenue CAGR stands at 15.13% and net profit CAGR at 20.95%, demonstrating consistent growth.
+Emcure Pharma holds a strong business performance score of 100 and a growth score of 76.
+The stock has delivered strong returns, with a 60.79% gain over the last year.
BEAR CASE
−FIIs decreased their stake by 0.24% QoQ to 3.35% in Q4 FY26.
−ML predictions for 1-year Free Cash Flow (FCF) growth are weak, ranking 0.11 for recent 2-year model and 0.0 for rolling 4-year and stable 7-year models.
−The stock is trading at a PE of 34.77, higher than sector peer Dr. Reddy's at 19.55.
−The intrinsic value model is currently unreliable due to predicted severe FCF compression.
−The dividend yield is relatively low at 0.17% compared to some sector peers.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹2580 Cr
+22.85% YoY
NET PROFIT
₹292 Cr
+36.17% YoY
OPM
20.7%
+0.72pp YoY
EPS
₹15.5
PE 34.77
Intrinsic value · DCF ₹2072.15 · Margin of safety +7.6% (fair) · FCF yield 1.6%
◇ Sector Position
Emcure's PE of 34.77 is competitive, though higher than Dr. Reddy's (19.55) and Cipla (29.52), while its ROCE of 24.0% places it favorably among peers like Divi's Lab (21.47%) but below Dr. Reddy's (27.63%).
PEERPEROCE %
EMCURE34.7724.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
72
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
STRONG
90
Valuation
FAIR
40
Growth
STRONG
76
Profitability
HIGH
85
Technicals
NEUTRAL
52
Risk
LOW
90
Key Stats
TTM PE
34.77
P/B
6.5
52W HIGH
₹2048.0
OFF HIGH
-5.96%
DIV YIELD
0.17%
MKT CAP
₹36374 Cr
◉ Active Signals
MACDBearish-2.3786
RSI(14)Neutral57.19
Street Consensus
6 analysts₹1891.83
mean target
Low ₹1640.0Now ₹1925.9High ₹1976.0
⧉ Strategy Fit 🔒